Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studies

Journal of Clinical Pharmacology

Volumn 56, Issue 2, 2016, Pages 152-156

  Greenblatt, David J ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBICISTAT; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR; DESIPRAMINE; ITRACONAZOLE; MIDAZOLAM; RITONAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

AREA UNDER THE CURVE; DRUG DRUG INTERACTION; DRUG EXPOSURE; DRUG INTERACTION; DRUG METABOLISM; ENZYME INDUCTION; HUMAN; MEAL; NOTE; PRACTICE GUIDELINE;

CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; RITONAVIR;

EID: 84956623719     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.609     Document Type: Note

References (42)

1. Greenblatt DJ, von Moltke LL., Clinical studies of drug-drug interactions: design and interpretation. In: Pang KS, Rodrigues AD, Peter RM, eds. Enzyme and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges. New York: Springer 2010: 625-649.
2. Greenblatt DJ., The ketoconazole legacy. Clin Pharmacol Drug Dev. 2014; 3: 1-3.
3. Greenblatt HK, Greenblatt DJ., Liver injury associated with ketoconazole: review of the published evidence. J Clin Pharmacol. 2014; 54 (12): 1321-1329.
4. Raschi E, Poluzzi E, Koci A, Caraceni P, Ponti FD., Assessing liver injury associated with antimycotics: concise literature review and clues from data mining of the FAERS database. World J Hepatol. 2014; 6 (8): 601-612.
5. Greenblatt DJ, Harmatz JS., Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. Br J Clin Pharmacol. 2015; 80: 342-350.
6. Ke AB, Zamek-Gliszczynski MJ, Higgins JW, Hall SD., Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clin Pharmacol Ther. 2014; 95 (5): 473-476.
7. Liu L, Bello A, Dresser MJ, et al., Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. J Clin Pharmacol. 2015 [Epub ahead of print].
8. Tran TH, von Moltke LL, Venkatakrishnan K, et al., Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos. 2002; 30: 1441-1445.
9. von Moltke LL, Greenblatt DJ, Grassi JM, et al., Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol. 1998; 38: 106-111.
10. von Moltke LL, Durol ALB, Duan SX, Greenblatt DJ., Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol. 2000; 56: 259-261.
11. Rock BM, Hengel SM, Rock DA, Wienkers LC, Kunze KL., Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4. Mol Pharmacol. 2014; 86 (6): 665-674.
12. Mathias AA, West S, Hui J, Kearney BP., Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther. 2009; 85 (1): 64-70.
13. Eichbaum C, Cortese M, Blank A, Burhenne J, Mikus G., Concentration effect relationship of CYP3A inhibition by ritonavir in humans. Eur J Clin Pharmacol. 2013; 69 (10): 1795-1800.
14. Culm-Merdek KE, von Moltke LL, Gan L, et al., Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006 79: 243-254.
15. Greenblatt DJ, Peters DE, Oleson LE, et al., Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol. 2009; 68 (6): 920-927.
16. Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G., Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther. 2011; 90 (5): 666-673.
17. Olkkola K, Ahonen J, Neuvonen P., The effect of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996; 82: 511-516.
18. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ., Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos. 2001; 29 (2): 100-102.
19. Eagling VA, Back DJ, Barry MG., Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997; 44: 190-194.
20. Englund G, Lundquist P, Skogastierna C, et al., Cytochrome P450 inhibitory properties of common efflux transporter inhibitors. Drug Metab Dispos. 2014; 42 (3): 441-447.
21. Xu L, Liu H, Murray BP, et al., Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010; 1 (5): 209-213.
22. Niwa T, Shiraga T, Takagi A., Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005; 28 (9): 1805-1808.
23. Niwa T, Inoue-Yamamoto S, Shiraga T, Takagi A., Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol Pharm Bull. 2005; 28 (9): 1813-1816.
24. Kozakai K, Yamada Y, Oshikata M, et al., Cocktail-substrate approach-based high-throughput assay for evaluation of direct and time-dependent inhibition of multiple cytochrome P450 isoforms. Drug Metab Pharmacokinet. 2014; 29 (2): 198-207.
25. Walsky RL, Astuccio AV, Obach RS., Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006; 46 (12): 1426-1438.
26. Talakad JC, Kumar S, Halpert JR., Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab Dispos. 2009; 37 (3): 644-650.
27. Peltoniemi MA, Saari TI, Hagelberg NM, et al., Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther. 2011; 90 (2): 296-302.
28. Jiang F, Desta Z, Shon JH, et al., Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. Br J Clin Pharmacol. 2013; 75 (1): 244-253.
29. Kirby BJ, Collier AC, Kharasch ED, et al., Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos. 2011; 39 (12): 2329-2337.
30. Yeh RF, Gaver VE, Patterson KB, et al., Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006; 42 (1): 52-60.
31. Hafner V, Jager M, Matthee AK, et al., Effect of simultaneous induction and inhibition of CYP3A by St John's wort and ritonavir on CYP3A activity. Clin Pharmacol Ther. 2010; 87 (2): 191-196.
32. Kharasch E, Bedynek P, Walker A, Whittington D, Hoffer C., Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther. 2008; 84: 506-512.
33. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD., Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos. 2011; 39 (6): 1070-1078.
34. Klein CE, Chiu YL, Awni W, et al., The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007; 44 (4): 401-410.
35. Sekar V, Kestens D, Spinosa-Guzman S, et al., The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol. 2007; 47 (4): 479-484.
36. Lamorde M, Byakika-Kibwika P, Boffito M, et al., Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults. J Acquir Immune Defic Syndr. 2012; 60 (3): 295-298.
37. Morcos PN, Moreira SA, Navarro MT, et al., Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers. J Pharm Pharmacol. 2014; 66 (1): 23-31.
38. Greenblatt DJ., Antiretroviral boosting by cobicistat, a structural analog of ritonavir. Clin Pharmacol Drug Dev. 2014; 3: 335-337.
39. Mathias AA, German P, Murray BP, et al., Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010; 87 (3): 322-329.
40. Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, et al., Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 2005; 78 (6): 664-674.
41. Gallant JE, Koenig E, Andrade-Villanueva J, et al., Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. 2013; 208 (1): 32-39.
42. Gallant JE, Koenig E, Andrade-Villanueva JF, et al., Cobicistat compared with ritonavir as a pharmacoenhancer for atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate: week 144 results. J Acquir Immune Defic Syndr. 2015; 69 (3): 338-340.